Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Risk Analysis

• Publication date

  1993-02-01

• Fields of study

  Medicine, Chemistry, Environmental Science

• Identifiers
  DOI 10.1111/J.1539-6924.1993.TB00726.XPMID 8383868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological and physiological factors involved in disposition of dioxin and related compounds

  1992cited by this paper
• Targets for dioxin: genes for plasminogen activator inhibitor-2 and interleukin-1 beta.

  1991cited by this paper
• Ovarian hormones enhance 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated increases in cell proliferation and preneoplastic foci in a two-stage model for rat hepatocarcinogenesis.

  1991cited by this paper
• Downregulation of the Ah receptor in mouse hepatoma cells treated in culture with 2,3,7,8-tetrachlorodibenzo-p-dioxin.

  1991cited by this paper
• Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat: biliary excretion and induction of cytochromes CYP1A1 and CYP1A2.

  1991cited by this paper
• Comparison of the nuclear and cytosolic forms of the Ah receptor from Hepa 1c1c7 cells: charge heterogeneity and ATP binding properties.

  1991cited by this paper
• A perspective on biologically-based approaches to dioxin risk assessment.

  1991cited by this paper
• Characterization of polyclonal antibodies to the Ah receptor prepared by immunization with a synthetic peptide hapten.

  1991cited by this paper
• A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat.

  1990cited by this paper
• The specific DNA binding activity of the dioxin receptor is modulated by the 90 kd heat shock protein.

  1990cited by this paper
• Pharmacokinetics of [125I]-2-iodo-3,7,8-trichlorodibenzo-p-dioxin in mice: analysis with a physiological modeling approach.

  1990cited by this paper
• Genetic and molecular aspects of 2,3,7,8-tetrachlorodibenzo-p-dioxin action.

  1990cited by this paper
• TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) is a tight binding inhibitor of cytochrome P-450d.

  1989cited by this paper
• Distribution of PCDDs and PCDFs in rat tissues following various routes of administration

  1989cited by this paper
• [125I]2-iodo-3,7,8-trichlorodibenzo-p-dioxin-binding species in mouse liver induced by agonists for the Ah receptor: characterization and identification.

  1989cited by this paper
• Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin

  1989cited by this paper
• A physiologically based pharmacokinetic model for 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J and DBA/2J mice.

  1988cited by this paper
• A competitive binding assay for 2,3,7,8-tetrachlorodibenzo-p-dioxin and related ligands of the Ah receptor.

  1988cited by this paper
• Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin

  1988cited by this paper
• In vivo kinetics and DNA-binding properties of the Ah receptor in the golden Syrian hamster.

  1988cited by this paper
• Assessing the elimination of 2,3,7,8-TCDD from humans with a physiologically based pharmacokinetic model

  1988cited by this paper
• A method to quantitate the relative initiating and promoting potencies of hepatocarcinogenic agents in their dose-response relationships to altered hepatic foci.

  1987cited by this paper
• Dose-dependent elevation of Ah receptor binding by TCDD in rat liver.

  1987cited by this paper
• Cytosolic receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Evidence for a homologous nature among various mammalian species.

  1984cited by this paper
• Pharmacokinetics of PCBs.

  1984cited by this paper
• Pharmacokinetics of PCBs

  1984cited by this paper
• Physiological model for the pharmacokinetics of 2,3,7,8-tetrachlorodibenzofuran in several species.

  1983cited by this paper
• Tissue distribution, excretion, and metabolism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the Golden Syrian hamster.

  1980cited by this paper
• Quantitative evaluation of the promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin of hepatocarcinogenesis from diethylnitrosamine.

  1980cited by this paper
• Three-generation reproduction study of rats given 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the diet.

  1979cited by this paper
• 2,3,7,8-Tetrachlorodibenzo-p-dioxin tissue distribution, excretion, and effects on clinical chemical parameters in guinea pigs.

  1979cited by this paper
• Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats.

  1978cited by this paper
• The fate of 2,3,7,8-tetrachlorodibenzo-p-dioxin following single and repeated oral doses to the rat.

  1976cited by this paper
• Organs as targets of “dioxin” (2,3,7,8-tetrachlorodibenzo-p-dioxin) intoxication

  1972cited by this paper
• Teratology studies with 2,4,5-trichlorophenoxyacetic acid and 2,3,7,8-tetrachlorodibenzo-p-dioxin.

  1971cited by this paper

• Physiologically-based Pharmacokinetic Modeling: a Supportive Tool to Evaluate Polychlorinated Biphenyls

  2020cites this paper
• Physiologically based toxicokinetic models and in silico predicted partition coefficients to estimate tetrachlorodibenzo-p-dioxin transfer from feed into growing pigs

  2019cites this paper
• Risk for animal and human health related to the presence of dioxins and dioxin‐like PCBs in feed and food

  2018cites this paper
• Physiologically Based Pharmacokinetic Models in the Risk Assessment of Developmental Neurotoxicants

  2018cites this paper
• Physiologically based pharmacokinetic toolkit to evaluate environmental exposures: Applications of the dioxin model to study real life exposures

  2017cites this paper
• Assessing body burden of persistent organic pollutants (POPs) in infants/toddlers through analysis of faeces

  2017cites this paper
• My Winding Road: From Microbiology to Toxicology and Environmental Health.

  2016cites this paper
• Uncertainty analysis in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) cancer dose-response for three occupational cohorts.

  2016cites this paper
• Mode of action and dose–response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study

  2014cites this paper
• Statistical Estimation of Physiologically-based Pharmacokinetic Models: Identifiability, Variation, and Uncertainty with an Illustration of Chronic Exposure to Dioxin and Dioxin-like-compounds.

  2012cites this paper
• Pharmacokinetics of 2,3,7,8‐Tetrachlorodibenzo‐P‐Dioxin and Related Compounds

  2012cites this paper
• Physiologically based pharmacokinetic/toxicokinetic modeling.

  2012cites this paper
• Multi-Dose-Route, Multi-Species Pharmacokinetic Models for Manganese and Their Use in Risk Assessment

  2010cites this paper
• A Molecular Perspective on Exposure–Dose–Response

  2010cites this paper
• Effects of dietary assessment methods on assessing risk of nutrient intake adequacy at the population level: from theory to practice

  2009cites this paper
• Approaches for Applications of Physiologically Based Pharmacokinetic Models in Risk Assessment

  2008cites this paper
• 2,3,4,7,8-Pentachlorodibenzofuran using both Non-linear and Linear Approaches

  2008cites this paper
• COMPARTMENTAL AND PERFUSIONAL APPROACHES FOR PHARMACOKINETICAL MODELS CONSTRUCTION

  2008cites this paper
• Estimates of cancer potency of 2,3,4,7,8-pentachlorodibenzofuran using both nonlinear and linear approaches.

  2008cites this paper
• A possible role of multidrug resistance-associated protein 2 (Mrp2) in hepatic excretion of PCB126, an environmental contaminant: PBPK/PD modeling.

  2008cites this paper
• Pharmacokinetic Modeling of Manganese in the Rat IV: Assessing Factors that Contribute to Brain Accumulation During Inhalation Exposure

  2008cites this paper
• Hepatic sequestration of chlordecone and hexafluoroacetone evaluated by pharmacokinetic modeling.

  2007cites this paper
• On the incorporation of biokinetic and mechanistic data in modeling for risk assessment

  2007cites this paper
• Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat.

  2006cites this paper
• Use of a Physiologically Based Pharmacokinetic Model for Rats to Study the Influence of Body Fat Mass and Induction of CYP1A2 on the Pharmacokinetics of TCDD

  2006influential citation
• Estimated cancer risk of dioxins to humans using a bioassay and physiologically based pharmacokinetic model.

  2006cites this paper
• Carcinogenic risks of dioxin: mechanistic considerations.

  2005cites this paper
• Comparison of the Use of a Physiologically Based Pharmacokinetic Model and a Classical Pharmacokinetic Model for Dioxin Exposure Assessments

  2005cites this paper
• Mechanistic approaches for mixture risk assessments-present capabilities with simple mixtures and future directions.

  2004cites this paper
• Dioxin health risk to infants using simulated tissue concentrations.

  2004influential citation
• Development of a Physiologically Based Pharmacokinetic Model for Decane, a Constituent of Jet Propellent-8

  2004cites this paper
• Physiologically based pharmacokinetic model for developmental exposures to TCDD in the rat.

  2004cites this paper
• Toxicokinetics and Physiologically Based Toxicokinetics in Toxicology and Risk Assessment

  2003cites this paper
• Improving Risk Assessment : Toxicological Research Needs 1

  2003cites this paper
• Simulation of dioxin accumulation in human tissues and analysis of reproductive risk.

  2003cites this paper
• Modélisation toxicocinétique de la concentration sanguine de 2,3,7,8‐tétrachloro‐ p ‐dioxine après ingestion chez la femme

  2003cites this paper
• PII: S0045-6535(97)00108-2

  2003cites this paper
• Toxicokinetic modeling and its applications in chemical risk assessment.

  2003cites this paper
• Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmacokinetic models for trichloroethylene.

  2003cites this paper
• Toxicokinetic modeling for environmental health problems

  2003cites this paper
• Closed-Chamber Inhalation Pharmacokinetic Studies with Hexamethyldisiloxane in the Rat

  2003cites this paper
• Dose-response modeling of cytochrome p450 induction in rats by octamethylcyclotetrasiloxane.

  2002cites this paper
• The Use of Quantitative Histological and Molecular Data for Risk Assessment and Biologically Based Model Development

  2002cites this paper
• Modeling the Uptake and Disposition of Hydrophobic Organic Chemicals in Fish Using a Physiologically Based Approach

  2002cites this paper
• Determination of tissue-blood partition coefficients for a physiological model for humans, and estimation of dioxin concentration in tissues.

  2002cites this paper
• Population toxicokinetic analysis of 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin using Bayesian techniques

  2002cites this paper
• Improving Risk Assessment: Toxicological Research Needs

  2002cites this paper
• Toxicokinetic Models: Where We've Been and Where We Need to Go!

  2002cites this paper
• Human Exposure and Fate

  2001cites this paper
• Physiological modeling of a proposed mechanism of enzyme induction by TCDD.

  2001cites this paper
• Subchronic Exposure of [3H]- 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in female B6C3F1 mice: relationship of steady-state levels to disposition and metabolism.

  2001cites this paper
• Comparative toxicokinetics of tetrachlorobenzyltoluenes (TCBTs) and polychlorobiphenyls (PCBs)

  2001cites this paper
• Predictions for a distributed parameter model describing the hepatic processing of 2,3,7,8-TCDD

  2001cites this paper
• A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment.

  2001cites this paper
• Physiologically based pharmacokinetic model for tetrachlorobenzyltoluenes in rat: comparison of in vitro and in vivo metabolic rates.

  2001cites this paper
• Mode of action and tissue dosimetry in current and future risk assessments.

  2001cites this paper
• Dose-response relationships for induction of CYP1A1 and CYP1A2 enzyme activity in liver, lung, and skin in female mice following subchronic exposure to polychlorinated biphenyls.

  2000cites this paper
• Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat.

  2000cites this paper
• Risk ranges for various endpoints following exposure to 2,3,7,8-TCDD

  2000cites this paper
• Relative contributions of affinity and intrinsic efficacy to aryl hydrocarbon receptor ligand potency.

  2000cites this paper
• Toxicological profile for polychlorinated biphenyls (PCBs)

  2000cites this paper
• Relative lipid content as the sole mechanistic determinant of the adipose tissue:blood partition coefficients of highly lipophilic organic chemicals.

  2000cites this paper
• Dioxines dans l'environnement : quels risques pour la santé ?

  2000cites this paper
• Characterization of a Perfusion Reactor Utilizing Mammalian Cells on Microcarrier Beads

  2000cites this paper
• Toxicokinetics

  2000cites this paper
• Live Tumor-Promoting Effect of β-Naphthoflavone, a Strong CYP 1A1/2 Inducer, and the Relationship between CYP 1A1/2 Induction and Cx32 Decrease in Its Hepatocarcinogenesis in the Rat

  2000cites this paper
• Quantitative evaluation of alternative mechanisms of blood disposition of di(n-butyl) phthalate and mono(n-butyl) phthalate in rats.

  2000cites this paper
• Contribution of planar (0-1 ortho) and nonplanar (2-4 ortho) fractions of Aroclor 1260 to the induction of altered hepatic foci in female Sprague-Dawley rats.

  2000cites this paper
• Mechanistic aspects the dioxin (aryl hydrocarbon) receptor

  2000cites this paper
• Liver Tumor Promotion by .BETA.-Naphthoflavone, a Strong CYP 1A1/2 Inducer, in a 28 Week Two-stage Rat Hepatocarcinogenesis Model Using Diethylnitrosamine as an Initiator.

  2000cites this paper
• EFFECTS OF TCDD ON THYROID HORMONE HOMEOSTASIS IN THE RAT

  2000cites this paper
• Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species.

  2000cites this paper
• Quantitative mechanistically based dose-response modeling with endocrine-active compounds.

  1999cites this paper
• Uncertainty in Estimating Exposure Using a Toxicokinetic Model: The Example of 2,3,7,8‐Tetrachlorodibenzo‐p‐Dioxin

  1999cites this paper
• Physiological Modeling of Benzo(a)pyrene Pharmacokinetics in the Rat

  1999cites this paper
• Quantitative evaluation of alternative mechanisms of blood and testes disposition of di(2-ethylhexyl) phthalate and mono(2-ethylhexyl) phthalate in rats.

  1999cites this paper
• Dose-dependent localization of TCDD in isolated centrilobular and periportal hepatocytes.

  1999cites this paper
• Regulations and Advisories

  1999cites this paper
• Uncertainty in Biomonitoring and Kinetic Modeling

  1999cites this paper
• Induction of altered hepatic foci by a mixture of dioxin-like compounds with and without 2,2',4,4',5,5'-hexachlorobiphenyl in female Sprague-Dawley rats.

  1999cites this paper
• Mechanistic modeling of rodent liver tumor promotion at low levels of exposure: an example related to dose-response relationships for 2,3,7,8-tetrachlorodibenzo-p-dioxin

  1998cites this paper
• A pharmacodynamic analysis of TCDD-induced cytochrome P450 gene expression in multiple tissues: dose- and time-dependent effects.

  1998cites this paper
• Predictions for a Distributed Parameter Model Describing the Hepatic Processing of 2,3,7,8-tcdd

  1998cites this paper
• Estimation of occupational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin using a minimal physiologic toxicokinetic model.

  1998cites this paper
• Endocrine active compounds: from biology to dose response assessment.

  1998cites this paper
• Physiological modeling of toxicokinetic interactions: implications for mixture risk assessment.

  1998cites this paper
• The use of biochemical and molecular parameters to estimate dose-response relationships at low levels of exposure.

  1998cites this paper
• Dose-response relationships for disposition and hepatic sequestration of polyhalogenated dibenzo-p-dioxins, dibenzofurans, and biphenyls following subchronic treatment in mice.

  1998cites this paper
• Physiologically-based pharmacokinetic modeling of pyrene in the rat.

  1998influential citation
• Power-frequency fields and cancer.

  1998cites this paper
• Toxicokinetics of an environmentally relevant mixture of dioxin-like PHAHs with or without a non-dioxin-like PCB in a semi-chronic exposure study in female Sprague Dawley rats.

  1998cites this paper
• Physiologically based toxicokinetic model for maternal transfer of 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin in brook trout (Salvelinus fontinalis)

  1998cites this paper
• Effect of subchronic 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on immune system and target gene responses in mice: calculation of benchmark doses for CYP1A1 and CYP1A2 related enzyme activities

  1997cites this paper
• A multicompartment geometric model of the liver in relation to regional induction of cytochrome P450s.

  1997cites this paper
• Determination of parameters responsible for pharmacokinetic behavior of TCDD in female Sprague-Dawley rats.

  1997cites this paper
• A pharmacokinetic analysis of interspecies extrapolation in dioxin risk assessment.

  1997cites this paper
• Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation.

  1997cites this paper
• Dose–Response Relationships for Polyhalogenated Dioxins and Dibenzofurans Following Subchronic Treatment in Mice

  1997cites this paper
• 2,3,7,8-Tetrachlorodibenzo-p -dioxin (TCDD) and congeners in infants. A toxicokinetic model of human lifetime body burden by TCDD with special emphasis on its uptake by nutrition

  1997influential citation
• Dose-response relationships for polyhalogenated dioxins and dibenzofurans following subchronic treatment in mice. I. CYP1A1 and CYP1A2 enzyme activity in liver, lung, and skin.

  1997cites this paper